Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 48 entries
View as:

A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

Phase: N/A Priority: Normal
NCT ID: NCT02110225 Org: User:
Start: 01/31/14 End: 11/30/15 Due: 11/30/16

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT03031470 Org: User:
Start: 03/10/15 End: 03/31/17 Due: 03/31/18

Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup

Phase: N/A Priority: Normal
NCT ID: NCT02858193 Org: User:
Start: 07/04/16 End: 10/10/16 Due: 10/10/17

Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00224406 Org: User:
Start: 05/01/05 End: 09/13/07 Due: 09/13/08

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

Phase: N/A Priority: Normal
NCT ID: NCT01571895 Org: User:
Start: 02/20/12 End: 07/05/12 Due: 07/05/13

Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

Phase: N/A Priority: Normal
NCT ID: NCT06411132 Org: User:
Start: 05/09/24 End: 01/10/25 Due: 01/10/26

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

Phase: N/A Priority: Normal
NCT ID: NCT03982368 Org: User:
Start: 06/10/19 End: 07/15/20 Due: 07/15/21

Reparixin in COVID-19 Pneumonia - Efficacy and Safety

Phase: N/A Priority: Normal
NCT ID: NCT04794803 Org: User:
Start: 05/05/20 End: 02/02/21 Due: 02/02/22

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT05136170 Org: User:
Start: 01/27/22 End: 05/24/23 Due: 05/24/24

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT01817959 Org: User:
Start: 10/31/12 End: 12/31/17 Due: 12/31/18

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

Phase: N/A Priority: Normal
NCT ID: NCT03019627 Org: User:
Start: 01/20/17 End: 08/31/17 Due: 08/31/18

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Phase: N/A Priority: Normal
NCT ID: NCT02855450 Org: User:
Start: 12/31/16 End: 05/31/18 Due: 05/31/19

Reparixin in Pancreatic Islet Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT01220856 Org: User:
Start: 07/28/10 End: 04/30/13 Due: 04/30/14

Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01861054 Org: User:
Start: 02/28/13 End: 03/01/16 Due: 03/01/17

Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

Phase: N/A Priority: Normal
NCT ID: NCT01756456 Org: User:
Start: 01/31/13 End: 05/31/16 Due: 05/31/17

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT05035368 Org: User:
Start: 09/30/21 End: 06/30/23 Due: 06/30/24

Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.

Phase: N/A Priority: Normal
NCT ID: NCT03031327 Org: User:
Start: 06/17/17 End: 08/10/17 Due: 08/10/18

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03836859 Org: User:
Start: 03/30/18 End: 06/01/18 Due: 06/01/19

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Phase: N/A Priority: Normal
NCT ID: NCT04899271 Org: User:
Start: 12/14/20 End: 10/11/23 Due: 10/11/24

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01744704 Org: User:
Start: 07/31/12 End: 03/31/13 Due: 03/31/14

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

Phase: N/A Priority: Normal
NCT ID: NCT02101281 Org: User:
Start: 01/20/14 End: 01/31/15 Due: 01/31/16

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Phase: N/A Priority: Normal
NCT ID: NCT04628481 Org: User:
Start: 01/12/21 End: 04/30/26 Due: 04/30/27

A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02814838 Org: User:
Start: 08/31/16 End: 05/15/19 Due: 05/15/20

Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Phase: N/A Priority: Normal
NCT ID: NCT02001974 Org: User:
Start: 02/27/12 End: 01/15/15 Due: 01/15/16

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT00248040 Org: User:
Start: 10/31/05 End: 06/30/08 Due: 06/30/09